Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 11, 2014, Pages 1359-1373

  Weissmann, Norbert ^a   Lobo, Borja ^b   Pichl, Alexandra ^a   Parajuli, Nirmal ^a   Seimetz, Michael ^a   Puig Pey, Raquel ^b   Ferrer, Elisabet ^b   Peinado, Víctor I ^b,c   Domińguez Fandos, David ^b   Fysikopoulos, Athanasios ^a   Stasch, Johannes Peter ^d   Ghofrani, Hossein A ^a   Coll Bonfill, Núria ^b   Frey, Reiner ^d   Schermuly, Ralph T ^a   García Lucio, Jéssica ^b   Blanco, Isabel ^b,c   Bednorz, Mariola ^a   Tura Ceide, Olga ^b,c   Tadele, Elsa ^a   Brandes, Ralf P ^e   Grimminger, Jan ^a   Klepetko, Walter ^f   Jaksch, Peter ^f   Rodriguez Roisin, Robert ^b,c   Seeger, Werner ^a,g   Grimminger, Friedrich ^a   Barberà, Joan A ^b,c   more..

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d BAYER PHARMA AG   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

Chronic obstructive pulmonary disease; Emphysema; Pharmacology; Pulmonary hypertension; Soluble guanylate cyclase

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CD18 ANTIGEN; CIGARETTE SMOKE; CYCLIC GMP; GUANYLATE CYCLASE; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; PEROXYNITRITE; RIOCIGUAT; SOLUBLE GUANYLATE CYCLASE ALPHA1; SOLUBLE GUANYLATE CYCLASE ALPHA2; SOLUBLE GUANYLATE CYCLASE BETA1; SOLUBLE GUANYLATE CYCLASE BETA2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTERIAL PRESSURE; ARTICLE; CELL ADHESION; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; GUINEA PIG; HEART VENTRICLE VOLUME; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG ALVEOLUS CELL; LUNG ARTERY PRESSURE; LUNG COMPLIANCE; LUNG EMPHYSEMA; LUNG HEMODYNAMICS; LUNG PARENCHYMA; MALE; MORPHOMETRICS; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; TIDAL VOLUME; TREATMENT DURATION; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DOWN-REGULATION; EMPHYSEMA; GUANYLATE CYCLASE; GUINEA PIGS; HUMANS; HYPERTENSION, PULMONARY; MICE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SMOKING;

EID: 84901787971     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201311-2037OC     Document Type: Article

References (61)

1. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-365.
2. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-280. (Pubitemid 30490396)
3. Yoshida T, Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev 2007;87:1047-1082. (Pubitemid 47084676)
4. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653. (Pubitemid 38787999)
5. Cosio MG, Majo J, Cosio MG. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest 2002;121(5, Suppl)160S-165S. (Pubitemid 34497335)
6. Peinado VI, Pizarro S, Barberà JA. Pulmonary vascular involvement in COPD. Chest 2008;134:808-814.
7. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 2010;137(6, Suppl)39S-51S.
8. Barberà JA, Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs 2009;69:1153-1171.
9. Santos S, Peinado VI, Ramirez J, Morales-Blanhir J, Bastos R, Roca J, Rodriguez-Roisin R, Barbera JA. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1250-1256. (Pubitemid 36555098)
10. Seimetz M, Parajuli N, Pichl A, Veit F, Kwapiszewska G, Weisel FC,Milger K, Egemnazarov B, Turowska A, Fuchs B, et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011;147:293-305.
11. Ferrer E, Peinado VI, Castañeda J, Prieto-Lloret J, Olea E, González-Martín MC, Vega-Agapito MV, Díez M, Domínguez-Fandos D, Obeso A, et al. Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig. Eur Respir J 2011;38:617-627.
12. Derbyshire ER, Marletta MA. Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem 2012;81:533-559.
13. Pyriochou A, Papapetropoulos A. Soluble guanylyl cyclase: more secrets revealed. Cell Signal 2005;17:407-413. (Pubitemid 39643059)
14. Schermuly RT, Janssen W, Weissmann N, Stasch JP, Grimminger F, Ghofrani HA. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs 2011;20:567-576.
15. Harteneck C, Wedel B, Koesling D, Malkewitz J, Böhme E, Schultz G. Molecular cloning and expression of a new alpha-subunit of soluble guanylyl cyclase. Interchangeability of the alpha-subunits of the enzyme. FEBS Lett 1991;292:217-222.
16. Yuen PS, Potter LR, Garbers DL. A new form of guanylyl cyclase is preferentially expressed in rat kidney. Biochemistry 1990;29:10872-10878.
17. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755-768. (Pubitemid 44323702)
18. Lang M, Kojonazarov B, Tian X, Kalymbetov A, Weissmann N, Grimminger F, Kretschmer A, Stasch JP, Seeger W, Ghofrani HA, et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS ONE 2012;7:e43433.
19. Schermuly RT, Stasch JP, Pullamsetti SS, Middendorff R, Müller D, Schlüter KD, Dingendorf A, Hackemack S, Kolosionek E, Kaulen C, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008;32:881-891.
20. Feil R, Kemp-Harper B. cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications. EMBO Rep 2006;7:149 -153.
21. Joshi CN, Martin DN, Fox JC, Mendelev NN, Brown TA, Tulis DA. The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways. J Pharmacol Exp Ther 2011;339:394 -402.
22. Ahluwalia A, Foster P, Scotland RS, McLean PG, Mathur A, Perretti M, Moncada S, Hobbs AJ. Antiin flammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 2004;101:1386-1391. (Pubitemid 38182698)
23. Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, Beckhaus T, Wagner K, Matt S, Gegenbauer K, Geschka S, et al. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res 2009;105:33-41.
24. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging the rapeutic target in cardiopulmonary disease. Circulation 2011;123:2263-2273.
25. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006;116:2552-2561. (Pubitemid 44330154)
26. Tabima DM, Frizzell S, Gladwin MT. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med 2012;52:1970-1986.
27. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006;113:286-295.
28. Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J, Ewert R, Weimann G, Grimminger F. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36:792-799.
29. Hoeper MM, Halank M, Wilkens H, Gunther A, Weimann G, Gebert I, Leuchte H, Behr J. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J 2013;41:853-860.
30. Weissmann N, Hackemack S, Dahal BK, Pullamsetti SS, Savai R, Mittal M, Fuchs B, Medebach T, Dumitrascu R, Eickels Mv, et al. Thesoluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 2009;297:L658-L665.
31. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, et al.; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-340.
32. Wright JLCA, Churg A. A model of tobacco smoke-induced airflow obstruction in the guinea pig. Chest 2002;121(5, Suppl)188S-191S. (Pubitemid 34497338)
33. Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol 2008;294:L612-L631. (Pubitemid 351520094)
34. Padilla-Carlin DJ, McMurray DN, Hickey AJ. The guinea pig as a model of infectious diseases. Comp Med 2008;58:324-340.
35. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410:212-215. (Pubitemid 32216593)
36. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, et al. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 2002;136:773-783. (Pubitemid 34785720)
37. Pichl A, Parajuli N, Seimetz M, Stasch JP, Frey R, Schermuly RT, Seeger W, Grimminger F, Ghofrani HA, Weissmann N. Stimulation of soluble guanylate cyclase by riociguat prevents tobacco smoke-induced pulmonary hypertension in mice. Thieme Pneumologie 2012;66:A310.
38. Lobo BP-PR, Ferrer E, Dominguez-Fandos D, Coll N, Garcia J, Musri MM, Peinado VI, Barbera JA. Stimulation of soluble guanylate cyclase in guinea pigs chronically exposed to cigarette smoke reduces intrapulmonary vascular remodeling and prevents emphysema. Am J Respir Crit Care Med 2013;187:A4666.
39. Pichl A, Parajuli N, Seimetz M, Stasch JP, Frey R, Schermuly RT, Seeger W, Grimminger F, Ghofrani HA, Weissmann N. The soluble guanylate cylase stimulator riociguat prevents from tobacco smoke-induced pulmonary hypertension and emphysema. Presented at the Pulmonary Vascular Research Institute Workshops & Debates. January 25, 2013, Istanbul, Turkey.
40. Seimetz M, Parajuli N, Pichl A, Stasch JP, Frey R, Schermuly RT, Ghofrani HA, Seeger W, Grimminger F, Weissmann N. Effects of the soluble guanylate cyclase stimulator riociguat on emphysema development in tobacco-smoke exposed mice. Am J Respir Crit Care Med 2011;183:A3107.
41. Seimetz M, Parajuli N, Pichl A, Stasch JP, Frey R, Schermuly RT, Ghofrani HA, Seeger W, Grimminger F, Weissmann N. Prevention of cigarette smoke-induced pulmonary hypertension by the soluble guanylate cyclase stimulator riociguat. Am J Respir Crit Care Med 2012;185;A3416.
42. Peinado VI, Gómez FP, Barberà JA, Roman A, Angels Montero M, Ramírez J, Roca J, Rodriguez-Roisin R. Pulmonary vascular abnormalities in chronic obstructive pulmonary disease undergoing lung transplant. J Heart Lung Transplant 2013;32:1262-1269.
43. Li H, Förstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000;190:244-254. (Pubitemid 30141371)
44. Chiche JD, Schlutsmeyer SM, Bloch DB, de la Monte SM, Roberts JD Jr, Filippov G, Janssens SP, Rosenzweig A, Bloch KD. Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. J Biol Chem 1998;273:34263-34271.
45. Mendelev NN, Williams VS, Tulis DA. Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells. J Cardiovasc Pharmacol 2009;53:121-131.
46. Wedgwood S, Steinhorn RH, Bunderson M, Wilham J, Lakshminrusimha S, Brennan LA, Black SM. Increased hydrogen peroxide down regulates soluble guanylate cyclase in the lungs of lambs with persistent pulmonary hypertension of the newborn. Am J Physiol Lung Cell Mol Physiol 2005;289:L660-L666. (Pubitemid 41361676)
47. Sekine K, Ohuchi H, Fujiwara M, Yamasaki M, Yoshizawa T, Sato T, Yagishita N, Matsui D, Koga Y, Itoh N, et al. Fgf10 is essential for limb and lung formation. Nat Genet 1999;21:138-141. (Pubitemid 29036301)
48. Ramasamy SK, Mailleux AA, Gupte VV, Mata F, Sala FG, Veltmaat JM, Del Moral PM, De Langhe S, Parsa S, Kelly LK, et al. Fgf10 dosage is critical for the amplification of epithelial cell progenitors and for the formation of multiple mesenchymal lineages during lung development. Dev Biol 2007;307:237-247. (Pubitemid 47008914)
49. Liu PXB, Xu B, Hock CE, Nagele R, Sun FF, Wong PY. NO modulates P-selectin and ICAM-1 mRNA expression and hemodynamic alterations in hepatic I/R. Am J Physiol 1998;275:H2191-H2198.
50. Overbeek SABS, Braber S, Henricks PA, Kleinjan M, Kamp VM, Georgiou NA, Garssen J, Kraneveld AD, Folkerts G. Cigarette smoke induces β2-integrin-dependent neutrophil migration across human endothelium. Respir Res 2011;12:75.
51. Canalli AA, Franco-Penteado CF, Saad ST, Conran N, Costa FF. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica 2008;93:605-609.
52. Dal-Secco DFA, Freitas A, Abreu MA, Garlet TP, Rossi MA, Ferreira SH, Silva JS, Alves-Filho JC, Cunha FQ. Reduction of ICAM-1 expression by carbon monoxide via soluble guanylate cyclase activation accounts for modulation of neutrophil migration. Naunyn Schmiedebergs Arch Pharmacol 2010;381:483-493.
53. Morbidelli LPA, Pyriochou A, Filippi S, Vasileiadis I, Roussos C, Zhou Z, Loutrari H, Waltenberger J, Stössel A, Giannis A, et al. The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability. Am J Physiol Regul Integr Comp Physiol 2010;298:R824-R832.
54. Wright JL, Zhou S, Preobrazhenska O, Marshall C, Sin DD, Laher I, Golbidi S, Churg AM. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med 2011;183:50-58.
55. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371-1385.
56. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004;110:2253- 2259.
57. Ghofrani HA, Voswinckel R, Gall H, Schermuly R, Weissmann N, Seeger W, Grimminger F. Riociguat for pulmonary hypertension. Future Cardiol 2010;6:155-166.
58. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bölkow D, Weissmann N, Mück W, Unger S, Wensing G, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33:785-792.
59. Masuyama HTT, Tsuruda T, Kato J, Imamura T, Asada Y, Stasch JP, Kitamura K, Eto T. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension 2006;48:972-978. (Pubitemid 44611012)
60. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, et al.; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-2903.
61. Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thébaud B. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med 2005;172:750-756. (Pubitemid 41324231)